


Product Information



Bezafibrate

Item No. 10009145

CAS Registry No.: 41859-67-0
Formal Name: 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid
Synonyms: Benzoifibrate, BM 15075, Bezalip, Bezatrol, Difaterol
MF: C₁₉H₂₀ClNO₄
FW: 361.8
Purity: ≥98%
Stability: ≥2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max}: 229 nm



Laboratory Procedures

For long term storage, we suggest that bezafibrate be stored as supplied at -20°C. It should be stable for at least two years.

Bezafibrate is supplied as a crystalline solid. A stock solution may be made by dissolving the bezafibrate in an organic solvent purged with an inert gas. Bezafibrate is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of bezafibrate in ethanol is approximately 3 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Bezafibrate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, bezafibrate should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Bezafibrate has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Bezafibrate is a well established pan-peroxisome proliferator-activated receptor (pan-PPAR) activator. This fibrate drug has over 25 years of therapeutic use with a good safety profile. The fibrate class of drugs are generally known as PPARα agonists, but bezafibrate appears to activate PPARδ and PPARγ as well. Bezafibrate activates human PPARα, PPARδ, and PPARγ with EC₅₀ values of 50, 20, and 60 μM, respectively, in a cell-based transcription assay.¹ Bezafibrate is used to treat hyperlipidemia. It helps lower low-density lipoprotein cholesterol and triglycerides while raising high-density lipoprotein cholesterol levels. It also improves insulin sensitivity and reduces blood glucose levels, which in combination with the cholesterol effects significantly lowers the incidence of cardiovascular events and development of diabetes in patients with features of metabolic syndrome.²

References

- Willson, T.M., Brown, P.J., Sternbach, D.D., *et al.* The PPARs: From orphan receptors to drug discovery. *J. Med. Chem.* **43**(4), 528-550 (2000).
- Tenenbaum, A., Motro, M., and Fisman, E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons. *Cardiovascular Diabetology* **4**(14), 1-5 (2005).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/10009145

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 04/04/2012